Pillar Biosciences received premarket approval from FDA for its ONCO/Reveal™ Dx Lung and Colon Cancer Assay

Aug, 2021

Home  >  Resources  >  Press Release  > Pillar Biosciences received premarket approval from FDA for its ONCO/Reveal™ Dx Lung and Colon Cancer Assay

Pillar Biosciences announced the U.S. Food and Drug Administration (FDA) has given Premarket Approval (PMA) to its ONCO/Reveal™ Dx Lung and Colon Cancer Assay, an NGS tissue-based companion diagnostic test for the qualitative detection of somatic mutations in DNA derived from non-small cell lung cancer (NSCLC) and colorectal (CRC) cancer tumors.

Please click here for details.

Scroll to Top